Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

NEUROMETRIX, INC.

(NURO)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

NeuroMetrix, Inc. Announces Date for Third Quarter 2021 Financial Results Conference Call

10/14/2021 | 09:01am EST

WOBURN, Mass., Oct. 14, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2021 third quarter financial results before the opening of the market on October 21, 2021. The Company will host a conference call at 8:00 a.m., Eastern Time on October 21, 2021 to discuss its financial results as well as business developments affecting the Company.

The conference call may be accessed in the United States by dialing 844-787-0799 and using the confirmation code 7683407. Internationally, the conference call may be accessed by dialing 661-378-9630 and using the same confirmation code. The earnings press release and accompanying condensed financial statements will be accessible from the Company's website at www.NeuroMetrix.com under the "Investor Relations" tab.

A replay of the conference call will be available starting two hours after the call by dialing 855-859-2056, domestically and 404-537-3406, internationally. The confirmation code to access the replay is 7683407. The replay will be available for one week after the conference call.

About NeuroMetrix

NeuroMetrix is an innovation-driven company focused on the development and global commercialization of non-invasive medical devices for the diagnosis and treatment of pain and neurological disorders. The Company has three commercial products. DPNCheck® is a diagnostic device that provides rapid, point-of-care detection of peripheral neuropathies. ADVANCE® is a diagnostic device that provides automated, in-office nerve conduction studies for the evaluation of entrapment neuropathies. Quell® is a wearable neurostimulation device indicated for treatment of lower extremity chronic pain. For more information, visit www.NeuroMetrix.com.

NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761
SVP and Chief Financial Officer
neurometrix.ir@neurometrix.com

Source: NeuroMetrix, Inc.

 


Primary Logo


ę GlobeNewswire 2021
All news about NEUROMETRIX, INC.
12/03NEUROMETRIX, INC. : Changes in Registrant's Certifying Accountant, Financial Statements an..
AQ
10/22NEUROMETRIX, INC. : Entry into a Material Definitive Agreement, Financial Statements and E..
AQ
10/21NEUROMETRIX : Management's Discussion and Analysis of Financial Condition and Results of O..
AQ
10/21NeuroMetrix, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended ..
CI
10/21NEUROMETRIX : Reports Q3 2021 Financial Results - Form 8-K
PU
10/21NEUROMETRIX : Earnings Flash (NURO) NEUROMETRIX Reports Q3 Revenue $2.1M
MT
10/21NeuroMetrix Reports Q3 2021 Financial Results
GL
10/20NeuroMetrix, Inc. Names Susan M. Bell, RN, BN, as Senior Vice President of Population H..
CI
10/14NeuroMetrix, Inc. Announces Date for Third Quarter 2021 Financial Results Conference Ca..
GL
10/07NeuroMetrix Shares Rise 10% After Submitting De Novo Request for Quell
DJ
More news
Financials (USD)
Sales 2020 7,38 M - -
Net income 2020 -2,09 M - -
Net cash 2020 4,17 M - -
P/E ratio 2020 -4,55x
Yield 2020 -
Capitalization 43,7 M 43,7 M -
EV / Sales 2019 0,28x
EV / Sales 2020 1,06x
Nbr of Employees 20
Free-Float 99,5%
Chart NEUROMETRIX, INC.
Duration : Period :
NeuroMetrix, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NEUROMETRIX, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Managers and Directors
Shai N. Gozani Chairman, President & Chief Executive Officer
Thomas T. Higgins Chief Financial Officer, Treasurer & Senior VP
David E. Goodman Independent Director
Nancy E. Katz Independent Director
David van Avermaete Independent Director
Sector and Competitors
1st jan.Capi. (M$)
NEUROMETRIX, INC.107.28%44
ABBOTT LABORATORIES20.94%234 157
MEDTRONIC PLC-4.16%150 954
BECTON, DICKINSON AND COMPANY0.06%71 108
HOYA CORPORATION25.65%58 237
DEXCOM, INC.51.03%54 121